Highlight
- Intra-arterial tenecteplase administered after successful reperfusion by thrombectomy shows tolerable safety at low doses in large vessel occlusion stroke.
- Dose escalation revealed unacceptable hemorrhagic risk at 0.1250 mg/kg, but doses 0.0313 mg/kg and 0.0625 mg/kg were safe for further study.
- Preliminary efficacy signals suggest a trend toward improved 90-day functional independence but were not statistically significant in this early-phase trial.
- Findings support progressing to larger randomized trials to clarify therapeutic benefit and optimize dosing strategies.
Study Background and Disease Burden
Specialty calculators
For clinical reference; use professional judgment.
